Results 251 to 260 of about 345,011 (339)

Tau‐targeting active immunotherapy slows progression and reduces pathology in mouse models of tauopathy

Brain Pathology, EarlyView.
The efficacy of the novel anti‐tau active immunotherapy, p5555kb, was tested using two mouse models of tau pathology. p5555kb inoculation increased the survival rate and reduced tau pathology in tau‐overexpressing P301L mice and decreased tau seeding in the brains of C57BL/6 mice injected with human‐purified Alzheimer's disease tau.
Christopher M. Brown, Jeanne K. Brooks, Louise Kelly, Madeline M. Vroom, Matthew Longo, Jean‐Cosme Dodart, Roxana Carare, Justin D. Boyd   +7 more
wiley   +1 more source

Differential chromatin accessibility response to retinoic acid in neuroblastoma with ATRX in-frame-deletions versus ATRX loss-of-function. [PDF]

Neoplasia
Lorenzi F, Shipley M, Deane L, Goldstone R, Tandon V, da Costa BM, Greenslade K, Barker K, Nemati F, Bellini A, Schleiermacher G, Chesler L, Guillemot F, George SL.   +13 more
europepmc   +1 more source

Immunohistochemistry as a tool for identifying EGFR amplification in CNS tumors

Brain Pathology, EarlyView.
EGFR gene amplification constitutes a diagnostic hallmark for glioblastoma, IDH‐wildtype (GB, IDH‐WT). Herein, we demonstrated that EGFR IHC is a highly specific and sensitive biomarker for identifying EGFR amplification and should be part of the neuropathologist's routine panel of antibodies.
Arnault Tauziède‐Espariat, Mary Bah, Farah Sassi, Noémie Pucelle, Charlotte Berthaud, Marion Mandoula, Zeina Dababou, Noah Carnes, Leïla Brissez, Lauren Hasty, Euphrasie Servant, Alice Métais, Pascale Varlet   +12 more
wiley   +1 more source

PHLDA1 silencing in IMR-32 human neuroblastoma cells results in ABCB1 overexpression, augments chemoresistance and leads to increased growth of tumors. [PDF]

Sci Rep
Kudrycka M, Horwacik I, Brożyna AA, Żywicka M, Durbas M, Rokita H.   +5 more
europepmc   +1 more source

Effects mediated by M2 muscarinic orthosteric agonist on cell growth in human neuroblastoma cell lines

, 2019
Anna Maria Lucianò, Francesca Romana Mattei, Elisa Damo, Elisa Panzarini, Luciana Dini, Ada Maria Tata   +5 more
openalex   +1 more source

Overview and recent advances in the treatment of neuroblastoma

Expert Review of Anticancer Therapy, 2017
Sarah B Whittle, Valeria R Smith, E. Doherty, Sibo Zhao, S. McCarty, P. Zage   +5 more
semanticscholar   +1 more source

System level network data and models attack cancer drug resistance

British Journal of Pharmacology, EarlyView.
Drug resistance is responsible for >90% of cancer related deaths. Cancer drug resistance is a system level network phenomenon covering the entire cell. Small‐scale interactomes and signalling network models of drug resistance guide directed drug development.
Márk Kerestély, Dávid Keresztes, Levente Szarka, Borbála M. Kovács, Klára Schulc, Dániel V. Veres, Peter Csermely   +6 more
wiley   +1 more source

D3-GPC2-Directed CAR T Cells Are Safe and Efficacious in Preclinical Models of Neuroblastoma and Small Cell Lung Cancer. [PDF]

Clin Cancer Res
Giudice AM, Matlaga S, Roth SL, Gladney W, Groff D, Hofmann TJ, McDaid KS, Pascual-Pasto G, McIntyre B, Zecchino V, Martinez D, Spear TT, Wolpaw AJ, Assenmacher CA, Radaelli E, Pogoriler J, Pawel B, Barrett D, Grupp SA, Maris JM, Bosse KR.   +20 more
europepmc   +1 more source

Evidence that 5‐HT2A receptor signalling efficacy and not biased agonism differentiates serotonergic psychedelic from non‐psychedelic drugs

British Journal of Pharmacology, EarlyView.
Background and Purpose Serotonergic psychedelic drugs are under investigation as therapies for various psychiatric disorders, including major depression. Although serotonergic psychedelic drugs are 5‐HT2A receptor agonists, some such agonists are not psychedelic, potentially due to differences in 5‐HT2A receptor ligand bias or signalling efficacy. Here,
Aurelija Ippolito, Sridhar Vasudevan, Shaun Hurley, Gary Gilmour, Frederick Westhorpe, Grant Churchill, Trevor Sharp   +6 more
wiley   +1 more source

HLA-Shuttle: A system for enhancing antigen presentation in immunologically cold tumors. [PDF]

Sci Adv
Hwang D, Erdman MC, Adhikari S, Pantula R, Epstein K, Li P, Costabile F, Rotsides P, Wang CS, Sun SM, Fazelinia H, Spruce LA, Fugmann T, Rrustemi T, Soh WT, Farrel A, Want MY, Facciabene A, Mir M, Maris JM, Sgourakis NG.   +20 more
europepmc   +1 more source